Tag: Bristol
Bristol Myers: encouraging results for repotrectinib
(CercleFinance.com) – Bristol Myers Squibb today announced updated results from a study demonstrating that repotrectinib – a tyrosine kinase (TKI) inhibitor – continues to show high and durable response rates…
Bristol Myers: Encouraging results for repotrectinib
Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service…
Bristol Myers: Ulcerative Colitis Education Campaign
(CercleFinance.com) – Bristol Myers Squibb has launched Supporting You with UC, an educational campaign on ulcerative colitis (UC) with Rosie White, Patient Ambassador, Women’s World Cup commentator, former professional soccer…
Bristol Myers Squibb: FDA Approved Production Site
(CercleFinance.com) – Bristol Myers Squibb announced yesterday that the US Food and Drug Administration (FDA) has approved commercial production at the company’s brand new cell therapy production site in Devens,…
Bristol Myers: Positive CHMP Opinion for Reblozyl
Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service…
Bristol Myers: positive CHMP opinion for Reblozyl
(CercleFinance.com) – Bristol Myers Squibb has received a positive CHMP opinion for Reblozyl (luspatercept) in adult patients with anemia-associated non-transfusion-dependent beta-thalassemia (ATN). The recommendation will now be considered by the…
Bristol Myers: A Breakthrough for Melanoma Survival
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
Bristol Myers: New Data in Psoriasis
(CercleFinance.com) – Bristol Myers Squibb announces new long-term data on Sotyktu TM (deucravacitinib) showing sustained clinical efficacy for up to two years in case of continuous treatment in moderate to…
Bristol Myers: Failure of a phase 3 trial for cancer
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…